Proceedings of the 36th World Small Animal Veterinary Congress WSAVA

Size: px

Start display at page:

Download "Proceedings of the 36th World Small Animal Veterinary Congress WSAVA"

Stuart Carr
6 years ago
Views:

1 Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct , 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA

14(Fri) ~ 17(Mon) October 2011 ICC Jeju, Korea 2011 WSAVA FASAVA World Congress www.wsava2011.org OC-I09 CANINE MAMMARY TUMORS: TREATMENT, PROGNOSTIC FACTORS AND OUTCOME Karin U.

important treatment modality in canine mammary tumors. The goal of surgery is to remove all current tumors +/- prevent new tumors in the mammary glands.

Systemic therapy, including OHE and/or chemotherapy may be considered for these dogs.

2 14(Fri) ~ 17(Mon) October 2011 ICC Jeju, Korea 2011 WSAVA FASAVA World Congress OC-I09 CANINE MAMMARY TUMORS: TREATMENT, PROGNOSTIC FACTORS AND OUTCOME Karin U. Sorenmo, DVM, Dipl ACVIM, ECVIM-CA (oncology) Department of Clinical Studies, Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA Abstract Surgery represents the most important treatment modality in canine mammary tumors. The goal of surgery is to remove all current tumors +/- prevent new tumors in the mammary glands. Dogs with negative clinical or histopathological prognostic factors are not treated effectively with surgery alone. Systemic therapy, including OHE and/or chemotherapy may be considered for these dogs. Surgical Treatment Surgery is the mainstay of treatment in canine mammary tumors and can be curative in patients with benign tumors, low grade histology or early stage disease (small tumors). According to a large prospective randomized trial, there is no benefit to performing radical mastectomy compared to simple mastectomy, i.e. removing only the affected gland(s) in dogs with mammary tumors¹. No difference was found between remission and survival in dogs treated with radical versus simple mastectomy. Based on these findings, a standard surgical approach to mammary tumors has been adapted by many: Depending on the size, location and numbers of tumors, the surgery may include simple mastectomy, regional mastectomy radical mastectomy or a combination of these procedures. The goal of the surgery is to remove all current tumors with complete surgical margins. Prophylactic mastectomy of normal mammary glands is not indicated according to these guidelines. However, other publications have reported a very high incidence (50-95%) of new mammary tumors in dogs with a prior history of malignant tumors 2,3,4. One of these studies included only dogs with one mammary tumor and concluded that an ipsilateral mastectomy should be performed in such patients based on the high incidence of new tumors in the same chain 4. Another study included dogs with multiple tumors (70%), both sides were equally affected and new tumors developed in 50 % of dogs with prior malignant tumors³. These observations may suggest that prophylactic mastectomies may indeed have a role in selected high risk patients. However, there are currently no studies or guidelines to appropriately identify the dogs in which prophylactic mastectomy should be performed. Alternatively, owners should be advised that new tumors are common, further surgeries may be needed and therefore continued monitoring is important. However, some owners may be reluctant to subject their dogs to a second surgery. Unfortunately, an untreated new primary tumor and subsequent metastasis is, according to the WSAVA FASAVA World Congress Proceedings

3 CANINE MAMMARY TUMORS: TREATMENT, PROGNOSTIC FACTORS AND OUTCOME author s experience, not an uncommon cause of death in some of these dogs. A simple mastectomy, i.e. removal of the entire affected gland rather than a smaller procedure such as a lumpectomy may also be considered in patients with small tumors; studies have found a high incidence of high grade pre-neoplastic lesions adjacent to malignant lesions 2,5. A simple mastectomy will prevent progression and subsequent new tumors developing from such lesions. Canine mammary tumors represent a wide range of clinical presentations and biological behaviors; it is therefore not likely that one standard surgical guideline is appropriate for all cases. Further research is needed to better identify cases that benefit from prophylactic mastectomy so that the recommendations can be tailored to a patient s specific risk profile. Prognostic Factors Several prognostic factors have been identified in dogs with mammary gland tumors. These factors help identify patients that are not treated effectively with surgery alone and require systemic therapy. The most important clinical prognostic factors include tumor size, lymph node status and WHO stage. The histological prognostic factors include tumor type, histological grade and vascular invasion. Clinical prognostic factors: Tumor size has been found to be prognostic according to many independent investigators. Three different size categories are described in both staging systems: T1: < 3 cm, T2: 3-5 cm, and T3: > 5 cm. There is general agreement that size have prognostic significance, and these size categories capture crucial changes in prognosis based on tumor size alone 1,6,7. In reality there is likely a gradual change in prognosis with increasing tumor size, but the current size categories provide provides reliable prognostic information. Lymph node status is also important for prognosis. Metastasis to the local lymph node confirms a metastatic phenotype and implies metastasis beyond the affected lymph node. Several studies have confirmed that dogs with positive regional lymph nodes have a significantly worse prognosis than dogs with negative lymph nodes 6. In fact, tumor size becomes irrelevant if the local lymph nodes are involved. A positive local lymph node constitutes stage IV disease as indicated by the revised staging system, and is a clear indication for systemic therapy. WHO stage (both original and revised) has been shown to have prognostic significance. Information regarding tumor size and lymph node status are incorporated into the staging systems and since both of these factors carry prognostic significance by themselves, it is therefore not surprising that WHO stage also is prognostic. Several studies have shown that dogs with lower stage disease have a significantly better prognosis than dogs with advanced stage disease 7. Histopathological prognostic factors: Primary malignant mesenchymal mammary tumors (sarcomas) are associated with a guarded prognosis. Osteosarcomas are the most common primary mammary gland sarcomas and are characterized by aggressive biological behavior, similar osteosarcomas in other sites8. The WHO staging system used for epithelial tumors does not apply here; and it is important to note that sarcomas usually do not metastasis via the local lymph node but rather via the hematogenous route; therefore dogs with primary mammary gland osteosarcomas have a poor prognosis despite the absence of lymph node metastasis. Tumor grade is also predictive of outcome in dogs with epithelial tumors. The presence or absence of tubule formation, nuclear pleomorphism, and number of mitosis per 10HPF are evaluated and scored. Tumors are graded as grade I: well differentiated, grade II: intermediate, and grade III: undifferentiated. Despite subtle differences these grading systems are nevertheless useful in identifying dogs with aggressive tumors. Dogs with simple carcinomas have a worse prognosis than dogs with other carcinomas, and the presence of histological and 2011 WSAVA FASAVA World Congress Proceedings 761

4 vascular invasion is associated with a worse prognosis, and should therefore be considered when making decision regarding systemic therapy 8. Systemic Treatment and outcome Dogs with large tumors, lymph node metastasis or unfavorable histology are not treated effectively with local therapy alone. Dogs with distant metastasis are not likely to benefit from surgery, but may be palliated with chemotherapy. The options for systemic treatment in canine mammary tumors include hormonal therapy in the form of surgical ovarian hormonal ablation, i.e. ovariohysterectomy and/or chemotherapy. Hormonal therapy: The goal of hormonal therapy is to prevent carcinoma cells from receiving stimulation from hormones. This can be achieved through ovariohysterectomy (OHE) or medical means, such as specific estrogen receptor modulators (SERMS), suppression of estrogen synthesis by aromatase inhibitors or LHRH agonists. Tamoxifen, an estrogen receptor antagonist, commonly used in women with ER positive breast cancer, has also been evaluated in dogs, but due to the side effects, this is not a feasible option in dogs. OHE is a practical solution. The use of hormonal therapy in canine mammary tumors is based on the documentation of these tumors hormone dependence as well as the lessons learned from human breast cancer therapy where hormonal therapy has been found to significantly reduce recurrence and prolong survival in hormone receptor positive breast cancers. The results from the canine studies, all retrospective and non-randomized, however, are conflicting 9,10,11. Only a high powered prospective randomized trial where the effect of OHE stratified and analyzed in context of hormone receptor status can determine whether hormonal therapy has a role in dogs with mammary tumors. Chemotherapy: Similar to hormonal therapy, there are no prospective randomized trials on the effect of chemotherapy in dogs with high risk tumors. Nevertheless, chemotherapy is often used in dogs with negative prognostic factors. A prospective non-randomized study showed a significant survival benefit in dogs with high risk tumors (WHO stage III) treated with a combination of cyclophosphamide and 5-fluorouracil 12. Many oncologists also add doxorubicin to the above protocol. This is based on the fact that this is one of the most effective agents in high risk human breast cancer. No studies have confirmed its activity in dogs however. Primary mammary gland Osteosarcoma is highly aggressive and associated with a poor prognosis; similar protocols to those used for appendicular osteosarcomas may be useful in these cases. Case examples will be presented illustrating the use of systemic therapy and outcome in dogs with mammary tumors WSAVA FASAVA World Congress Proceedings

5 CANINE MAMMARY TUMORS: TREATMENT, PROGNOSTIC FACTORS AND OUTCOME References 1) MacEwen EG, Harvey HJ, Patnaik AK, et al Evaluation of the effect of levamizole and surgery on canine mammary cancer. J Biol Resp Mod 4, ) Gilbertson SR, Kurzman ID, Zachrau RE, et al Canine mammary epithelial neoplasms: Biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 20, ) Sorenmo KU, Kristiansen VM, Cofone MA, et al Canine mammary gland tumors; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 7, ) Stratmann N, Failing K, Richter A, et al Mammary tumor recurrence in bitches after regional mastectomy. Veterinary Surgery 37, ) Antuofermo E, Miller M, Pirino S, Xie J, Badve S, Mohammed SI Spontaneous Mammary Intraepithelial Lesions in Dogs-A model of Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention 16, ) Kurzman ID, Gilbertson SR Prognostic factors in canine mammary tumors. Semin Vet Med Surg 1, ) Yamagami T, Kobayashi T, Takahashi K Prognosis for canine malignant mammary tumors based on the TNM and histologic classification. J Vet Med Sci 58, ) Goldschmidt M, Pena L, Rasotto R Classification and grading of canine mammary tumors. Vet Pathol. 48, ) Schneider R, Dorn CR, Taylor DON: Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst. 43, ) Sorenmo, KU, Shofer FS, Goldschmidt MH 2000: Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med 14, ) Chang SC, Chang CC, Chang TJ, Wong ML prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases ( ).J Am Vet Med Assoc 227(10): , ) Karayannopoulo M, Kaldrymidou E, Constantinidis TC, et al Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med Series A 48, WSAVA FASAVA World Congress Proceedings 763

MAMMARY GLAND TUMORS General Information Pathology History & Clinical Signs

MAMMARY GLAND TUMORS General Information Pathology History & Clinical Signs MAMMARY GLAND TUMORS Philip J. Bergman DVM, MS, PhD, DACVIM (Oncology) Chief Medical Officer, BrightHeart Veterinary Centers, Armonk, NY 10504 pbergman@brightheartvet.com (914) 219-5415 (office), 219-5417